CPX-351, a novel liposomal encapsulation of daunorubicin and cytarabine, improved long-term overall survival and remission versus conventional 7+3 chemotherapy in a population of adults aged 60–75 years with high-risk or secondary acute myeloid leukaemia.

2018年9月10日 · Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged surviv …

Liposomal cytarabine-daunorubicin is 1 drug made up of 2 chemotherapy drugs: cytarabine. These drugs are combined into tiny particles called liposomes. The liposomes help the drugs to enter and kill the leukaemia cells. They allow the chemotherapy drugs to …

2021年1月6日 · CPX-351 was associated with a superior overall response rate (ORR) and overall survival (OS) compared with classical 7+3 (cytarabine and daunorubicin) intensive chemotherapy (IC).

2024年12月13日 · CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is an approved therapy for newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes in patients who are candidates for intensive chemotherapy. 1 In the primary analysis of the pivotal phase ...

2018年7月19日 · CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells.

Liposomal daunorubicin and cytarabine is a type of chemotherapy combination. It is also known as CPX351 and L-DA. You pronounce daunorubicin as daw-noh-roo-bih-sin and cytarabine as sye-ta-ra-bin. This is a treatment for acute myeloid leukaemia (AML).

CPX-351 is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. Primary analysis of the phase 3 trial in adults aged 60-75 years with newly diagnosed high-risk or secondary acute myeloid leukaemia provided support for approval of CPX-351 by the US Food and Drug Administration and European ...

CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a 1:5 molar ratio, is approved for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.

2022年10月26日 · CPX-351 (Europe: Vyxeos ® liposomal; United States: Vyxeos ®) is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. In a phase 3 study in older adults with newly diagnosed, high-risk/secondary AML, CPX-351 improved the remission frequency, overall survival, and post-transplant survival versus 7 + 3.